Arcutis Sinks ~20% as Q3 Earnings Miss on Surging SG&A, Guidance Still Raised
ARQT sits 40% above its 52-week low of $19.295.
Summary
Arcutis dropped nearly 20% Thursday after Q3 GAAP EPS of $0.06 missed consensus by $0.10, even though revenue of $143.9M beat by $1.3M and rose 45% year over year. The miss was expense-driven: net income of $8.8M came in well below the $20.7M analysts projected as R&D and SG&A climbed roughly 14% and 60% year over year to $22.4M and $99.6M, both above consensus. Management pinned the SG&A jump on its celebrity awareness campaign and a sales force expansion. Offsetting that, the company raised full-year net product sales guidance to $535M-$545M from $525M-$540M, implying about 45% growth at the midpoint and $156M-$166M for Q4. Analysts at Needham and Jefferies kept Buy ratings and $40/$39 targets, citing Zoryve demand and the new PCP/peds salesforce as drivers into 2027.
At the time of this announcement, ARQT was trading at $26.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $19.30 to $34.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.